3SBio (SEHK:1530) moved into focus after subsidiaries Zhejiang Sunshine Mandi and Zhejiang Wansheng signed an agreement with MindRank AI to commercialize MDR-001, an oral GLP-1 candidate in Phase 3 obesity trials.
Against that backdrop, 3SBio's recent agreement on MDR-001 lands after a tough stretch for holders, with the share price at HK$15.07 and the 1-year total shareholder return down 45.58% even as the 3-year total shareholder return is up more than 2x. The 30-day share price return declined 6.69% and the year-to-date share price return fell 38.69%. This suggests momentum has been fading and that fresh pipeline milestones like this GLP-1 deal are now helping investors reassess both growth potential and risk around the stock.
Spot fresh GLP-1 and healthcare AI opportunities by scanning a curated mix of 3SBio peers and adjacent plays in 127 healthcare AI stocks .
3SBio now looks like a classic timing call, with MDR-001 changing the story just as the share price has pulled back hard. Does it make more sense to step in now, or to wait for a cheaper entry as valuations line up next?
Preferred P/E of 3.9x for 3SBio: Is it justified?
On simple valuation math, 3SBio trades on a P/E of 3.9x, which screens as cheap against both its peers and the wider Hong Kong Biotechs industry.
The P/E ratio compares the current share price with earnings per share and, for a profitable drug developer like 3SBio, it gives a rough sense of how much investors are willing to pay for each unit of profit. A lower figure can signal that the market is assigning a cautious label to those earnings, especially for a pharmaceutical group where product cycles, regulatory risks and patent profiles matter a lot.
Context from the data suggests the current multiple is not just slightly below sector levels, it is far lower. 3SBio trades at 3.9x earnings, while the Hong Kong Biotechs industry average is 17.3x and the peer group average is 36.2x. The estimated fair P/E for 3SBio is 8.2x, which is more than double the current level and indicates a valuation that may be compared with that fair ratio if market expectations shift.
Explore the SWS fair ratio for 3SBio.
Result: Price-to-earnings of 3.9x (UNDERVALUED)
Still, the recent declines in revenue and net income, combined with a weak 1-year return, could pressure sentiment if MDR-001 progress is disappointing.
Find out about the key risks to this 3SBio narrative .
Another view on 3SBio's value
The low P/E points one way, but the SWS DCF model points even further. On that approach, 3SBio at HK$15.07 trades against an estimated future cash flow value of HK$33.62, which implies a very wide gap. Is the market correctly pricing in the forecast earnings and revenue declines, or overshooting?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out 3SBio for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 174 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed feelings about 3SBio after all that. If you want to move quickly and base your call on data rather than headlines, consider the 3 key rewards and 1 important warning sign
Looking for more 3SBio investment ideas next?
If 3SBio has sharpened your focus on valuation and risk, do not stop here. Broaden your watchlist with other ideas that fit your style.
-
Target potential value plays that combine quality fundamentals with beaten down prices by scanning the 174 high quality undervalued stocks .
-
Strengthen your income stream by reviewing the 223 dividend fortresses and focus on companies offering higher yields with robust payout profiles.
-
Prioritize resilience by searching the 222 resilient stocks with low risk scores to spot businesses with sturdier financials and lower risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 1530.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
